Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.39 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10891548 | 0.84 | PIK3CD (0.47) | SCN9ARAB9ANPC1PIK3CDPIK3CA | |
| SCHEMBL16698759 | 0.83 | SCN9A (0.70) | SCN9ARAB9ANPC1GRIA1CACNG8 | |
| SCHEMBL16707110 | 0.81 | SCN9A (0.70) | SCN9ARAB9ANPC1GRIA1CACNG8 | |
| SCHEMBL16698830 | 0.79 | SCN9A (0.61) | SCN9ARAB9ANPC1GRIA1CACNG8 | |
| SCHEMBL16698954 | 0.75 | SCN9A (0.56) | SCN9ARAB9ANPC1GRIA1CACNG8 | |
| SCHEMBL16698961 | 0.75 | SCN9A (0.56) | SCN9ARAB9ANPC1GRIA1CACNG8 | |
| SCHEMBL16698844 | 0.73 | SCN9A (0.55) | SCN9ARAB9ANPC1MCHR1MET | |
| SCHEMBL16699112 | 0.71 | SCN9A (1.00) | SCN9AMEN1KMT2AMCHR1 | |
| SCHEMBL10819080 | 0.70 | RAB9A (0.61) | SCN9ARAB9ANPC1GRIA1CACNG8 | |
| SCHEMBL16699280 | 0.66 | SCN9A (0.63) | SCN9ARAB9ANPC1GRIA1CACNG8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975858-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-05-22 | — | — | US | claimed |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-03-22 | — | — | US | claimed |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-05-14 | — | — | US | claimed |
| US-9975858-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975858-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975858-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-03-22 | — | — | US | disclosed |
| US-9828348-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828348-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828348-B2 | Benzimidazole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-05-14 | — | — | US | disclosed |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-05-14 | — | — | US | disclosed |
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133500-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | TRPV1, TRPV4, KCNA4 | SCN9A 120/4885RAB9A 3494/4885NPC1 3128/4885 |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | TRPV1, TRPV4, KCNA4 | SCN9A 120/4885RAB9A 3494/4885NPC1 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.